Association of retinal detachment with age 50 years or younger at onset in patients with acute retinal necrosis.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 20 09 2020
accepted: 18 03 2021
revised: 15 03 2021
pubmed: 14 4 2021
medline: 1 10 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

Due to the guarded prognosis of acute retinal necrosis (ARN), it is relevant to develop a strategy to early categorize those patients in a higher risk of worse outcomes. The purpose of this study is to describe clinical features and predictive factors for retinal detachment (RD) in patients with ARN. Retrospective observational case series of 34 adult patients (38 eyes) with ARN examined between January 2005 and July 2015 in the National Eye Institute (Bethesda, USA), the Department of Ophthalmology, University of Chile (Santiago, Chile), and APEC (CDMX, Mexico). A total of 16 males and 18 females with a mean age at presentation of 44.5 ± 16.8 years were included. Twenty-seven patients (79.4%) received intravenous acyclovir as first-line treatment, and 7 patients received either oral antiviral (4 patients) or oral plus intravitreal antiviral (3 patients). All subjects were treated with prednisone, with a mean initial dose of 57.7 ± 16.3 mg per day. Seventeen patients (50.0%) developed retinal detachment. An association of retinal detachment with age at onset was observed (p = 0.04), with patients younger than 50 years presenting a higher risk (OR = 14.86, p = 0.0009). Additionally, patients in this higher risk group had more inflammation in both anterior chamber and vitreous (p = 0.04 and 0.03, respectively). No other predictive factor for retinal detachment was found in the present study. RD represents an important complication in patients with ARN. Younger patients may be at higher risk of this complication, possibly secondary to the presence of a higher level of inflammation.

Sections du résumé

BACKGROUND BACKGROUND
Due to the guarded prognosis of acute retinal necrosis (ARN), it is relevant to develop a strategy to early categorize those patients in a higher risk of worse outcomes. The purpose of this study is to describe clinical features and predictive factors for retinal detachment (RD) in patients with ARN.
METHODS METHODS
Retrospective observational case series of 34 adult patients (38 eyes) with ARN examined between January 2005 and July 2015 in the National Eye Institute (Bethesda, USA), the Department of Ophthalmology, University of Chile (Santiago, Chile), and APEC (CDMX, Mexico).
RESULTS RESULTS
A total of 16 males and 18 females with a mean age at presentation of 44.5 ± 16.8 years were included. Twenty-seven patients (79.4%) received intravenous acyclovir as first-line treatment, and 7 patients received either oral antiviral (4 patients) or oral plus intravitreal antiviral (3 patients). All subjects were treated with prednisone, with a mean initial dose of 57.7 ± 16.3 mg per day. Seventeen patients (50.0%) developed retinal detachment. An association of retinal detachment with age at onset was observed (p = 0.04), with patients younger than 50 years presenting a higher risk (OR = 14.86, p = 0.0009). Additionally, patients in this higher risk group had more inflammation in both anterior chamber and vitreous (p = 0.04 and 0.03, respectively). No other predictive factor for retinal detachment was found in the present study.
CONCLUSIONS CONCLUSIONS
RD represents an important complication in patients with ARN. Younger patients may be at higher risk of this complication, possibly secondary to the presence of a higher level of inflammation.

Identifiants

pubmed: 33846837
doi: 10.1007/s00417-021-05166-4
pii: 10.1007/s00417-021-05166-4
doi:

Substances chimiques

Acyclovir X4HES1O11F

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2905-2911

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Muthiah MN, Michaelides M, Child CS, Mitchell SM (2007) Acute retinal necrosis: A national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol 91(11):1452–1455
doi: 10.1136/bjo.2007.114884
Holland GN, Standard diagnostic criteria for the acute retinal necrosis syndrome. (1994) Executive Committee of the American Uveitis Society. Am J Ophthalmol 117(5):663–667
doi: 10.1016/S0002-9394(14)70075-3
Roy R, Pal BP, Mathur G, Rao C, Das D, Biswas J (2014) Acute retinal necrosis: Clinical features, management and outcomes–A 10 year consecutive case series. Ocul Immunol Inflamm 22(3):170–174
doi: 10.3109/09273948.2013.819928
Lau CH, Missotten T, Salzmann J, Lightman SL (2007) Acute retinal necrosis features, management, and outcomes. Ophthalmology 114(4):756–762
doi: 10.1016/j.ophtha.2006.08.037
Wong RW, Jumper JM, McDonald HR, Johnson NR, Fu A, Lujan BJ, Cunningham ET Jr (2013) Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol 97(5):545–552
doi: 10.1136/bjophthalmol-2012-301983
Sims JL, Yeoh J, Stawell RJ (2009) Acute retinal necrosis: A case series with clinical features and treatment outcomes. Clin Exp Ophthalmol 37(5):473–477
doi: 10.1111/j.1442-9071.2009.02083.x
Wong R, Pavesio CE, Laidlaw DA, Williamson TH, Graham EM, Stanford MR (2010) Acute retinal necrosis: The effects of intravitreal foscarnet and virus type on outcome. Ophthalmology 117(3):556–560
doi: 10.1016/j.ophtha.2009.08.003
Park JJ, Pavesio C (2008) Prophylactic laser photocoagulation for acute retinal necrosis. Does it raise more questions than answers? Br J Ophthalmol 92(9):1161–1162
doi: 10.1136/bjo.2008.147181
Risseeuw S, de Boer JH, Ten Dam-van Loon NH, van Leeuwen R (2019) Risk of rhegmatogenous retinal detachment in acute retinal necrosis with and without prophylactic intervention. Am J Ophthalmol 206:140–148
doi: 10.1016/j.ajo.2019.05.023
Yeh S, Suhler EB, Smith JR et al (2014) Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome. Ophthalmic Surg Lasers Imaging Retina 45(5):399–407
doi: 10.3928/23258160-20140908-02
Winterhalter S, Stuebiger N, Maier AK et al (2016) Acute retinal necrosis: Diagnostic and treatment strategies in Germany. Ocul Immunol Inflamm 24(5):537–543
doi: 10.3109/09273948.2015.1034375
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 140(3):509–516
doi: 10.1016/j.ajo.2005.03.057
Butler NJ, Moradi A, Salek SS et al (2017) Acute retinal necrosis: Presenting characteristics and clinical outcomes in a cohort of polymerase chain reaction-positive patients. Am J Ophthalmol 179:179–189
doi: 10.1016/j.ajo.2017.05.006
Li AL, Fine HF, Shantha JG, Yeh S (2019) Update on the management of acute retinal necrosis. Ophthalmic Surg Lasers Imaging Retina 50(12):748–751
doi: 10.3928/23258160-20191119-01
Van Gelder RN, Willig JL, Holland GN, Kaplan HJ (2001) Herpes simplex virus type 2 as a cause of acute retinal necrosis syndrome in young patients. Ophthalmology 108(5):869–876
doi: 10.1016/S0161-6420(01)00556-5
Clark A, Morlet N, Ng JQ, Preen DB, Semmens JB (2012) Risk for retinal detachment after phacoemulsification: A whole-population study of cataract surgery outcomes. Arch Ophthalmol 130(7):882–888
doi: 10.1001/archophthalmol.2012.164
Kakehashi A, Kado M, Akiba J, Hirokawa H (1997) Variations of posterior vitreous detachment. Br J Ophthalmol 81(7):527–532
doi: 10.1136/bjo.81.7.527
Labalette P, Delhaes L, Margaron F, Fortier B, Rouland JF (2002) Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol 133(4):506–515
doi: 10.1016/S0002-9394(02)01324-7
Mitry D, Fleck BW, Wright AF, Campbell H, Charteris DG (2010) Pathogenesis of rhegmatogenous retinal detachment: Predisposing anatomy and cell biology. Retina 30(10):1561–1572
doi: 10.1097/IAE.0b013e3181f669e6

Auteurs

Cristhian A Urzua (CA)

Department, of Ophthalmology, Faculty of Medicine, University of Chile, Independencia 1027, Independencia, Santiago, Chile. cristhian.urzua@uchile.cl.
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA. cristhian.urzua@uchile.cl.
Laboratory of Autoimmune Ocular and Systemic Diseases, University of Chile, Santiago, Chile. cristhian.urzua@uchile.cl.
Clinica Alemana-Universidad del Desarrollo, Santiago, Chile. cristhian.urzua@uchile.cl.

Jared Knickelbein (J)

Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.

Loreto Cuitino (L)

Laboratory of Autoimmune Ocular and Systemic Diseases, University of Chile, Santiago, Chile.
Servicio de Oftalmología, Hospital Clínico Universidad de Chile, Santiago, Chile.

Uriel Moreno (U)

Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes" Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico.

Rodrigo Anguita (R)

Department, of Ophthalmology, Faculty of Medicine, University of Chile, Independencia 1027, Independencia, Santiago, Chile.

Victor Velasquez (V)

Hospital Del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Luz Elena Concha-Del-Rio (LE)

Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes" Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico.

Sergio Morales (S)

Hospital Del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Francisco A Villarroel (FA)

Hospital Del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

H Nida Sen (HN)

Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.

Lourdes Arellanes-Garcia (L)

Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes" Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH